Summary

Eligibility
for males ages 4 months to 5 years (full criteria)
Location
at Oakland, California and other locations
Dates
study started
completion around

Description

Summary

RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system. This study is a safety and efficacy, dose ranging study to determine whether RGX-121 is safe, effective and well-tolerated by patients with MPS II.

Official Title

A Phase 1/2/3 Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of RGX-121 in Pediatric Subjects With MPS II (Hunter Syndrome)

Details

Keywords

Mucopolysaccharidosis Type II (MPS II), MPS II, gene therapy, Hunter Syndrome, Lysosomal Storage Disorder, Mucopolysaccharidosis II, Mucopolysaccharidoses, RGX-121, RGX-121 Pivotal Expansion

Eligibility

Locations

  • UCSF, Benioff Children's Hospital
    Oakland California 94609 United States
  • Children's Hospital of Pittsburgh - UPMC: Program for Neurodevelopment in Rare Disorders
    Pittsburgh Pennsylvania 15224 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
REGENXBIO Inc.
ID
NCT03566043
Phase
Phase 2/3 research study
Study Type
Interventional
Participants
Expecting 48 study participants
Last Updated